Still there are many challenges and unanswered questions associated with ICI use, including the fact that the biomarkers currently in use — MSI-H/MMRd, high TMB, and PD-L1 IHC — are imperfect at best, probably because the immune reaction to cancer is tremendously complex. The gene discussed is CD274; the disease is cancer.